Abstract

Nanoparticles — particles in the size range 1–100 nm — are emerging as a class of therapeutics for cancer. Early clinical results suggest that nanoparticle therapeutics can show enhanced efficacy, while simultaneously reducing side effects, owing to properties such as more targeted localization in tumours and active cellular uptake. Here, we highlight the features of nanoparticle therapeutics that distinguish them from previous anticancer therapies, and describe how these features provide the potential for therapeutic effects that are not achievable with other modalities. While large numbers of preclinical studies have been published, the emphasis here is placed on preclinical and clinical studies that are likely to affect clinical investigations and their implications for advancing the treatment of patients with cancer.

Author affiliations

1. Chemical Engineering, California Institute of Technology, Pasadena, California 91125, USA.
2. Winship Cancer Institute, Emory School of Medicine, Atlanta, Georgia 30322, USA.

Correspondence to: Mark E. Davis¹ Email: mdavis@cheme.caltech.edu

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.